Shahrzad Mousavi, Mohammad Hossein Khazaee-Nasirabadi, Maryam Sadat Seyedmehdi, Ali Bazi, Roohollah Mirzaee Khalilabadi
{"title":"Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies.","authors":"Shahrzad Mousavi, Mohammad Hossein Khazaee-Nasirabadi, Maryam Sadat Seyedmehdi, Ali Bazi, Roohollah Mirzaee Khalilabadi","doi":"10.1080/10428194.2024.2438802","DOIUrl":null,"url":null,"abstract":"<p><p>In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies. However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i.e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-23"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2438802","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies. However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i.e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.
近来，CAR-T 细胞治疗的应用取得了重大进展，在血液恶性肿瘤中显示出良好的治疗效果。然而，在取得这些进展的同时，某些局限性和挑战也阻碍了这一技术的广泛应用。最近，CAR-NK 细胞在癌症治疗中备受关注，因为与 CART 疗法相比，这种方法在靶向外来细胞方面具有重要优势（即无需 HLA 匹配）。本综述旨在探讨 CAR NK 细胞疗法的优势、生成策略，以及阻碍 CAR NK 细胞在血液恶性肿瘤实验研究和试验中应用的挑战和限制。
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
